CorMedix CRMD
$5.27 +$0.19 (+3.74%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $5.32 +0.95%
Open$4.96
Prev close$5.08
Day range$4.95 – $5.32
Volume3.61M
Market cap$419.16M
P/E (TTM)8.2
Dividend yield–
Earnings
Average move on report day±13.1%last 16 reports
Closed higher8 of 1650% of the time
Best reaction+30.2%
Worst reaction-31.8%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 12 Nov 2026 | Pre Market | ±20.2% | -8.68% | Within range |
| 2026/Q2 | 13 Aug 2026 | Pre Market | ±13.5% | +14.65% | Bigger than priced |
| 2026/Q1 | 14 May 2026 | Pre Market | ±15.0% | +5.73% | Within range |
| 2025/Q4 | 5 Mar 2026 | Pre Market | ±14.9% | -11.52% | Within range |
| 2025/Q3 | 12 Nov 2025 | Pre Market | ±13.6% | +2.06% | Within range |
| 2025/Q2 | 7 Aug 2025 | Pre Market | ±18.3% | -9.54% | Within range |
| 2025/Q1 | 6 May 2025 | Pre Market | ±20.7% | +23.59% | Bigger than priced |
| 2024/Q4 | 25 Mar 2025 | Pre Market | ±21.4% | -31.85% | Bigger than priced |
| 2024/Q3 | 30 Oct 2024 | Pre Market | ±22.0% | -22.51% | Bigger than priced |
| 2024/Q2 | 14 Aug 2024 | Pre Market | ±19.1% | +30.16% | Bigger than priced |
| 2024/Q1 | 9 May 2024 | Pre Market | ±16.5% | -5.17% | Within range |
| 2023/Q4 | 12 Mar 2024 | Pre Market | ±20.0% | -2.84% | Within range |
| 2023/Q3 | 14 Nov 2023 | After Market | ±44.9% | +6.39% | Within range |
| 2023/Q2 | 8 Aug 2023 | Pre Market | ±20.6% | +7.94% | Within range |
| 2023/Q1 | 15 May 2023 | After Market | ±19.5% | -13.40% | Within range |
| 2022/Q4 | 30 Mar 2023 | Pre Market | ±27.6% | +13.11% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2026/Q2
By business line
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$51.26M-50.8% YoY
Operating profit-$6.62M-112.9% YoY
Net profit-$14.72M-113.6% YoY
Diluted EPS-$0.19-115.1% YoY
Free cash flow$87.79M+189.2% YoY
Operating cash flow$89.70M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin77.0%
Operating margin39.4%
Net margin15.6%
Return on equity15.1%
Return on assets7.5%
Return on invested capital11.1%
Current ratio2.43
Liabilities / assets49.7%
Cash & investments$355.15M
Total debt$145.42M
Net cash (debt)$209.73M
Free cash flow / sales76.2%
No comments yet — be the first to weigh in on CRMD.
Sign in to join the discussion.